Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VALTOCO vs DIASTAT ACUDIAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GABA-A receptor positive allosteric modulator; increases chloride ion conductance, hyperpolarizes neurons, and suppresses seizure activity.
Binds to GABA-A receptors, enhancing GABA effects and increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of seizure activity.
Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy aged 2 years and older
Status epilepticus,Acute repetitive seizures,Adjunctive treatment for epilepsy
5 mg, 10 mg, 15 mg, or 20 mg intranasally as a single dose based on weight; for patients weighing <50 kg: 5 mg, 10 mg for 50-75 kg, 15 mg for 75-100 kg, 20 mg for >100 kg. In adults, maximum dose is 20 mg per seizure cluster.
2.5 mg to 20 mg rectally, as a single dose for acute seizure clusters; may repeat once after 4-12 hours if needed. Maximum: 20 mg per treatment episode.
Terminal elimination half-life: 15-17 hours (range 11-20 h) in adults; no dose adjustment for age or renal impairment is recommended, but clinical monitoring is prudent in hepatic impairment.
Terminal elimination half-life: 20-50 hours in adults; prolonged in elderly and patients with hepatic impairment (up to 100 hours).
Hepatic via CYP3A4 and CYP2C9; active metabolite desmethyldiazepam (nordazepam)
Hepatic via CYP2C19, CYP3A4, and CYP2B6; major metabolite is N-desmethyldiazepam (active); also forms oxazepam and temazepam.
Renal (70% as unchanged drug and metabolites, primarily glucuronide conjugate, with <2% as unchanged drug); biliary/fecal (30%)
Primarily renal (urinary) as glucuronide conjugates and unchanged drug; <2% excreted unchanged in feces.
96% bound, primarily to albumin
97-99% bound primarily to albumin.
0.5-0.8 L/kg; approximates total body water, indicating extensive tissue distribution.
0.8-1.4 L/kg (adults); reflects extensive distribution into tissues including brain.
Intranasal: 75% (range 65-85%) relative to intravenous; rectal: 70-90% relative to intravenous.
Rectal gel: 80-100% relative to intravenous administration.
No dosage adjustment required for mild to moderate renal impairment. Severe renal impairment (e GFR <15 m L/min): consider using lower doses due to increased exposure; use with caution.
No specific dose adjustment provided in labeling; use with caution in severe renal impairment (Cr Cl < 10 m L/min) due to propylene glycol content.
Child-Pugh A or B: no adjustment needed. Child-Pugh C: reduce dose by 50% due to increased diazepam exposure.
Dose reduction may be necessary in Child-Pugh Class C cirrhosis; avoid in severe hepatic impairment due to decreased clearance and propylene glycol accumulation.
Age 6-17 years: 0.2 mg/kg intranasally, maximum single dose 20 mg. Administer as single dose per seizure cluster. Not recommended for children <6 years.
2 to 5 years: 0.5 mg/kg rectally; 6 to 11 years: 0.3 mg/kg; 12 years and older: 0.2 mg/kg. Dose per treatment episode not to exceed 20 mg.
Elderly patients may have increased sensitivity; consider starting at lower end of dosing range (5-10 mg) and titrate based on response and tolerability. Use with caution due to risk of sedation and falls.
Start at lower end of dosing range (2.5-5 mg) due to increased sensitivity and decreased clearance; monitor for excessive sedation and respiratory depression.
WARNING: RISK OF RESPIRATORY DEPRESSION AND CARDIAC ARREST WITH CONCOMITANT USE OF ALCOHOL OR OTHER CNS DEPRESSANTS; RISK OF SUBSTANCE ABUSE, DEPENDENCE, AND WITHDRAWAL; WITHDRAWAL SEIZURES; AND RISK OF SERIOUS SKIN REACTIONS.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve for patients with inadequate response to alternatives.
Risk of CNS depression and impaired motor function,Risk of abuse and dependence,Risk of withdrawal seizures upon abrupt discontinuation,Risk of serious skin reactions (e.g., Stevens-Johnson syndrome),Concomitant use with opioids may cause profound sedation, respiratory depression, coma, and death,Use in patients with compromised respiratory function or hepatic impairment requires caution
Risk of respiratory depression, particularly with high doses or in elderly/chronically ill; tolerance and dependence; withdrawal symptoms; may impair cognitive and motor functions; should not be abruptly discontinued.
Hypersensitivity to diazepam or any component of the formulation,Acute narrow-angle glaucoma,Concomitant use with opioid analgesics for acute treatment of seizure clusters (unless alternative treatments are not available)
Hypersensitivity to diazepam or benzodiazepines; narrow-angle glaucoma; severe respiratory insufficiency; myasthenia gravis; concomitant use with opioids (except for palliative care).
No specific food interactions. Avoid alcohol consumption during VALTOCO use as it may increase CNS depressant effects.
Grapefruit and grapefruit juice may increase diazepam levels and risk of toxicity; avoid concurrent consumption. Alcohol potentiates CNS depression and should be avoided. No other significant food interactions reported.
Diazepam (active moiety in VALTOCO) is Pregnancy Category D. First trimester: Associated with increased risk of congenital malformations, particularly cleft lip/palate, when used chronically. Second and third trimesters: May cause fetal benzodiazepine exposure leading to floppy infant syndrome, neonatal withdrawal, and central nervous system depression. Late third trimester or delivery: Risk of neonatal respiratory depression, hypotonia, and feeding difficulties.
DIASTAT ACUDIAL (diazepam) crosses the placenta. First trimester exposure is associated with a small increased risk of oral clefts (odds ratio ~1.5). In second and third trimesters, chronic use may lead to fetal benzodiazepine exposure; high doses near term can cause neonatal withdrawal (hypertonia, irritability, tremors, poor feeding) and 'floppy infant syndrome' (hypotonia, lethargy, respiratory depression). No known structural teratogenicity in later trimesters.
Diazepam is excreted into breast milk with an M/P ratio approximately 0.3. The relative infant dose is low (2-5% of weight-adjusted maternal dose). Caution is advised due to potential accumulation in neonates (long half-life) causing sedation, poor feeding, and respiratory depression. Use only if clearly needed with infant monitoring.
Diazepam is excreted into breast milk; M/P ratio is approximately 0.1-0.3. Relative infant dose estimated at 1-10% of maternal weight-adjusted dose. Neonatal accumulation possible due to long half-life (50-100 hours in preterm neonates). Breastfeeding is not recommended during chronic use due to risks of sedation, poor feeding, and withdrawal. Short-term, single-dose use may be acceptable with monitoring.
No specific dose adjustment recommended for VALTOCO during pregnancy for acute seizure management. However, due to increased volume of distribution and altered protein binding in pregnancy, a higher dose or more frequent dosing may be required for chronic use; clinical response should guide titration. Monitor for excessive sedation or respiratory depression as clearance may be reduced in late pregnancy.
Pregnancy increases volume of distribution and decreases albumin concentration, potentially reducing diazepam peak levels. However, drug clearance is unchanged or slightly decreased. Dose adjustments are individually determined based on clinical response; no fixed rule. Lower initial doses may be considered in third trimester due to enhanced drug sensitivity. After delivery, reduce dose to pre-pregnancy levels.
VALTOCO (diazepam nasal spray) is indicated for acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) in patients with epilepsy aged 6 years and older. Administer one spray into one nostril; if needed, a second spray into the opposite nostril can be given after 4 hours if seizure activity persists. Do not use more than two doses per episode. Onset of action is rapid (within 2-5 minutes). Monitor for respiratory depression, especially in patients with compromised respiratory function or concomitant CNS depressants. Each spray delivers 5 mg or 10 mg diazepam; the dose depends on patient weight (5 mg for <40 kg, 10 mg for ≥40 kg). Tilt patient's head back slightly during administration. Do not reuse the device; discard after use.
DIASTAT ACUDIAL is a diazepam rectal gel formulation used for acute repetitive seizures. Administer rectally; position patient on side to reduce aspiration risk. Do not administer more than 5 doses per month or more than 2 doses per single seizure episode. Monitor respiratory depression, especially with concurrent CNS depressants. Onset of action is 5-15 minutes; if seizure persists beyond 15 minutes, seek emergency medical attention. Avoid use in patients with acute narrow-angle glaucoma or severe liver disease.
Use VALTOCO exactly as prescribed; only for seizure clusters, not for daily seizures.,Administer one spray into one nostril; do not prime the device.,After administration, tilt head back slightly and breathe normally.,If seizure activity continues after 4 hours, a second dose may be given in the opposite nostril.,Do not use more than two doses per seizure episode; if ineffective, seek emergency medical help.,Store at room temperature (20-25°C); protect from light and moisture.,Keep out of reach of children; discard device after use.,May cause dizziness, drowsiness, or coordination problems; avoid driving or operating machinery until effects wear off.,Inform healthcare provider of all medications, especially CNS depressants (e.g., alcohol, opioids, sedatives).,Do not consume alcohol while using VALTOCO.
Use exactly as prescribed; do not exceed recommended doses.,Insert the rectal gel tip gently and hold buttocks together for 1-2 minutes after administration.,Keep a seizure diary to track episodes and medication use.,Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while using this drug.,Seek medical help if seizures worsen or if breathing difficulties occur.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VALTOCO vs DIASTAT ACUDIAL, answered by our medical review team.
VALTOCO is a Benzodiazepine Anticonvulsant that works by GABA-A receptor positive allosteric modulator; increases chloride ion conductance, hyperpolarizes neurons, and suppresses seizure activity.. DIASTAT ACUDIAL is a Benzodiazepine Anticonvulsant that works by Binds to GABA-A receptors, enhancing GABA effects and increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of seizure activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VALTOCO and DIASTAT ACUDIAL depend on the specific clinical indication. These are both Benzodiazepine Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VALTOCO is: 5 mg, 10 mg, 15 mg, or 20 mg intranasally as a single dose based on weight; for patients weighing <50 kg: 5 mg, 10 mg for 50-75 kg, 15 mg for 75-100 kg, 20 mg for >100 kg. In adults, maximum dose is 20 mg per seizure cluster.. The standard adult dose of DIASTAT ACUDIAL is: 2.5 mg to 20 mg rectally, as a single dose for acute seizure clusters; may repeat once after 4-12 hours if needed. Maximum: 20 mg per treatment episode.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VALTOCO and DIASTAT ACUDIAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VALTOCO is classified as Category C. Diazepam (active moiety in VALTOCO) is Pregnancy Category D. First trimester: Associated with increased risk of congenital malformations, particularly cleft lip/palate, when used c. DIASTAT ACUDIAL is classified as Category C. DIASTAT ACUDIAL (diazepam) crosses the placenta. First trimester exposure is associated with a small increased risk of oral clefts (odds ratio ~1.5). In second and third trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.